Quantitative, phenotypic, and functional evaluation of basophils in myelodysplastic syndromes

European Journal of Clinical Investigation

Volumn 31, Issue 10, 2001, Pages 894-901

  Fureder W ^a,d   Schernthaner, G H ^a,d   Ghannadan, M ^a,d   Hauswirth, A ^a,d   Sperr, W R ^a,d   Semper, H ^a,d   Majlesi, Y ^a,d   Zwirner, J ^b   Gotze O ^b   Buhring H J ^c   Lechner, K ^a,d   Valent, P ^a,d  

^a UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Basophils; Complement receptors; Histamine; MDS

Indexed keywords

ANTIGEN; CD11B ANTIGEN; CD203C ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3 RECEPTOR; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT COMPONENT C5A RECEPTOR; DECAY ACCELERATING FACTOR; GLYCOPROTEIN P 15095; HISTAMINE; IMMUNOGLOBULIN E; INTERLEUKIN 3 RECEPTOR; MEMBRANE COFACTOR PROTEIN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY DETECTION; ANTIGEN DETECTION; ANTIGEN EXPRESSION; ARTICLE; BASOPHIL; CELL COUNT; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTAMINE BLOOD LEVEL; HISTAMINE RELEASE; HUMAN; HUMAN CELL; MALE; MYELODYSPLASTIC SYNDROME; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, SURFACE; BASOPHILS; CASE-CONTROL STUDIES; FEMALE; HISTAMINE; HUMANS; LEUKOCYTE COUNT; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PHENOTYPE; RECEPTORS, COMPLEMENT; RECEPTORS, IGE; RECEPTORS, TRANSFERRIN;

EID: 0035740677     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2001.00887.x     Document Type: Article

References (41)

1. Treatment and prognostic factors in myelodysplastic syndromes
2. Epidemiologic perspectives on myelodysplastic syndromes and leukemia
3. Morphology and classification of the myelodysplastic syndromes and their pathologic variants
4. Morphologic classification of the myelodysplastic syndromes (MDS): Combined utilization of bone marrow aspirates and trephine biopsies
5. Prognostic factors and scoring systems in myelodysplastic syndromes
6. Infection in the myelodysplastic syndromes
7. Chronic myelodysplastic syndrome: Short survival with or without evolution to acute leukemia
8. Prognostic factors for survival of 194 patients with low infiltrative leukemia
9. Defective neutrophil function and microbicidal mechanisms in the myelodysplastic disorders
10. Blood neutrophil function in primary myelodysplastic syndromes
11. Neutrophils from patients with myelodysplastic syndromes: Relationship between impairment of granular contents, complement receptors, functional activities and disease status
12. Immunophenotypic characterization of myelomonocytic cells in patients with myelodysplastic syndrome
13. Altered surface expression of effector cell molecules on neutrophils in myelodysplastic syndromes
14. Complement receptor type 1 (CR1): Deficiency on neutrophils in myelodysplastic syndromes
15. Granulocyte Fc-IgG and C3b receptor expression in the primary myelodysplastic syndromes (MDS): Relationship with dysgranulopoiesis and evidence for heterogeneity of morphological subgroups
16. Molecular and cellular biology of mast cells and basophils
17. Mast cells and basophils in innate immunity
18. Secretion of IL-4 from human basophils. The relationship between IL-4 mRNA and protein in resting and stimulated basophils
19. IL-13 released by and localized in human basophils
20. The production of macrophage inflammatory protein-1 alpha by human basophils
21. Mediators of immediate hypersensitivity reactions
22. Interleukin-3 activates human basophils via high affinity binding sites
23. Complement induced histamine release from human basophils. I. Generation of activity in human serum
24. Interleukin 3 dependent mediator release in basophils triggered by C5a
25. Complement induced degranulation of human basophils
26. Proposals for the classification of the myelodysplastic syndromes
27. The chronic myeloid leukaemias: Guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia. Proposals by the French-American-British Cooperative Leukaemia Group
28. Evaluation of C3a receptor expression on human leukocytes by use of novel monoclonal antibodies
29. The monoclonal antibody 97A6 defines a novel surface antigen expressed on human basophils and their multipotent and unipotent progenitors
30. Blood- and skin-derived monocytes/macrophages respond to C3a but not to C3a (desArg) with a transient release of calcium via a pertussis sensitive signal transduction pathway
31. Mast cell typing: Demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes
32. Interleukin-3 is a differentiation factor for human basophils
33. Interleukin 3 and granulocyte/macrophage-colony-stimulating factor render human basophils responsive to low concentrations of complement component C3a
34. Cytogenetic clonality in myelodysplastic syndromes studied with fluorescence in situ hybridization: Lineage, response to growth factor therapy, and clone expansion
35. Evidence for nonclonal hematopoietic progenitor cell populations in bone marrow of patients with myelodysplastic syndromes
36. Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration
37. Membrane complement receptors specific for bound fragments of C3
38. Complement receptors
39. Differential expression of complement receptors on human basophils and mast cells: Evidence for mast cell heterogeneity and CD88/C5aR expression on skin mast cells
40. Demonstration of specific C5a receptor on intact human polymorphonuclear leukocytes
41. The basophil activation marker defined by antibody 97A6 is identical with the ecto-nucleotide pyrophosphatase / phosphodiesterase 3 (NPP-3; CD203c)